Lytix Biopharma AS
OSE:LYTIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lytix Biopharma AS
Income from Continuing Operations
Lytix Biopharma AS
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Income from Continuing Operations
-kr94.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Income from Continuing Operations
-kr134.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Income from Continuing Operations
kr9.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Income from Continuing Operations
-$12.2m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Income from Continuing Operations
-kr45.9m
|
CAGR 3-Years
53%
|
CAGR 5-Years
16%
|
CAGR 10-Years
7%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Income from Continuing Operations
-kr58m
|
CAGR 3-Years
49%
|
CAGR 5-Years
33%
|
CAGR 10-Years
1%
|
|
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
See Also
What is Lytix Biopharma AS's Income from Continuing Operations?
Income from Continuing Operations
-94.3m
NOK
Based on the financial report for Dec 31, 2024, Lytix Biopharma AS's Income from Continuing Operations amounts to -94.3m NOK.
What is Lytix Biopharma AS's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-23%
Over the last year, the Income from Continuing Operations growth was -7%. The average annual Income from Continuing Operations growth rates for Lytix Biopharma AS have been -25% over the past three years , -23% over the past five years .
